Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis

Syed Shahzad Hasan, Toby Capstick, Raees Ahmed, Chia Siang Kow, Faizan Mazhar, Hamid a Merchant and Syed Tabish Razi Zaidi

ABSTRACT

Objectives: The acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis is one of the main causes of high mortality in patients with COVID-19 (novel coronavirus disease 2019). We systematically reviewed mortality in COVID-19 patients with ARDS and the potential role of systemic corticosteroids in COVID-19 patients.

Methods: Electronic databases and country-specific healthcare databases were searched to identify relevant studies/reports. The quality assessment of individual studies was conducted using the Newcastle–Ottawa Scale. Country-specific proportion of individuals with COVID-19 who developed ARDS and reported death were combined in a random-effect meta-analysis to give a pooled mortality estimate of ARDS.

Results: The overall pooled mortality estimate among 10,815 ARDS cases in COVID-19 patients was 39% (95% CI: 23–56%). The pooled mortality estimate for China was 69% (95% CI: 67–72%). In Europe, the highest mortality estimate among COVID-19 patients with ARDS was reported in Poland (73%; 95% CI: 58–86%) while Germany had the lowest mortality estimate (13%; 95% CI: 2–29%) among COVID-19 patients with ARDS. The median crude mortality rate of COVID-19 patients with reported corticosteroid use was 28.0% (lower quartile: 13.9%; upper quartile: 53.6%).

Conclusions: The high mortality in COVID-19 associated ARDS necessitates a prompt and aggressive treatment strategy which includes corticosteroids. Most of the studies included no information on the dosing regimen of corticosteroid therapy, however, low-dose corticosteroid therapy or pulse corticosteroid therapy appears to have a beneficial role in the management of severely ill COVID-19 patients.

1. Introduction

A novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in late 2019 as the causative pathogen for an outbreak of severe pneumonia cases in Wuhan, China, later referred to as novel coronavirus disease 2019 (COVID-19). The unprecedented rate at which COVID-19 is spreading across the globe has perhaps surprised most of the epidemiologists in the world, which may be related to difficulties in the identification of asymptomatic SARS-CoV-2 carrier. While some patients had a relatively mild course of the disease, showing little or no symptoms, it was reported that about 20% of COVID-19 patients required hospitalization, mainly due to severe respiratory manifestations [1–7]. The major morbidity and mortality of hospitalized COVID-19 patients are attributed to acute viral pneumonitis leading to acute respiratory distress syndrome (ARDS) [1,2,8–10]. Based on the previously reported experience with SARS outbreak in 2003, a substantial number of patients (15–49%) developed respiratory failure leading to ARDS, with a mortality rate of 13–64% [11–14]. While SARS-CoV-2 is more contagious than SARS-CoV, the overall estimated case fatality rate of COVID-19 to date was lower than the SARS (0.82–9.64% versus 11%), and thus it is difficult to predict the fatality rate of COVID-19 patients upon the development of ARDS based on extrapolation from SARS patients [15,16]. Besides, there have been advancements in the management of ARDS since the SARS outbreak which occurred 17 years ago which may lead to more favorable clinical outcomes among COVID-19 patients with ARDS.

Corticosteroids were widely used during the 2002–03 outbreak of SARS in Mainland China and Hong Kong [17]. It was postulated that corticosteroid treatment may improve tissue injury in SARS caused by uncontrolled production of pro-inflammatory cytokines (e.g., interferon-gamma, tumor necrosis factor, interleukins (IL)-1 and IL-6) as an inflammatory response to viral infection [18,19]. A systematic review of 29 studies on corticosteroid use in patients with SARS [20] reported possible harms from corticosteroid use which include delayed virus clearance, increased risk of SARS-related psychosis, diabetes, and avascular necrosis. This has led to the WHO's
**Article highlights**

- Severe bilateral pneumonia developing into acute respiratory distress syndrome (ARDS) is one of the determinant factors for increased mortality in coronavirus disease 2019 (COVID-19).
- This systematic review and meta-analysis of original studies and country-specific reports assessed the mortality among COVID-19 patients with ARDS and to review the potential role of corticosteroids in COVID-19.
- Relatively high mortality was found with COVID-19 associated ARDS which demands an aggressive therapeutic intervention to prevent deaths.
- Despite the concerns that corticosteroids may hamper virus clearance, the low dose corticosteroids appear to have a role in the management of severely ill COVID-19 patients.

recommendation to avoid the routine use of systemic corticosteroid in COVID-19 beyond clinical trials [21]. However, closer scrutiny of the 2006 systematic review [20] revealed that the findings of most of the included studies reporting the efficacy of corticosteroids use were inconclusive, and thus it may be too early to discard corticosteroid therapy in our armamentarium against COVID-19.

Similar to SARS, it has recently been recognized that the pathophysiology of COVID-19 also involves the overproduction of proinflammatory cytokines, termed cytokine storm, that leads to enhanced vascular hyperpermeability which often triggers ARDS and hence the interest in exploring the role of corticosteroids in mitigating cytokine storm and its associated complications [22]. Specifically, in patients who develop ARDS, stimulation of glucocorticoid receptor with corticosteroids could down-regulate systemic and pulmonary inflammation, which is important to restore tissue homeostasis by accelerating resolution of diffuse alveolar damage and extrapulmonary organ dysfunction [23,24]. It is, therefore, important to revisit the recommendation for corticosteroid use in COVID-19 based on the most recent evidence. This article aimed to estimate the mortality among COVID-19 patients with ARDS and the effects of corticosteroid use on mortality. The article also provides a critical review of the potential roles of systemic corticosteroids in COVID-19, especially in terms of reducing ARDS-associated mortality, based on the currently available evidence to date.

2. Methods

2.1. Search strategy

This systematic review was conducted with adherence to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [25]. The following electronic literature databases were searched within March to July 2020 to identify eligible articles published in either English or Chinese languages between 1 December 2019 and 10 July 2020: PubMed (United States National Library of Medicine), Dimensions [26], and Google Scholar. We used the following search terms: ‘acute respiratory distress syndrome OR ARDS OR glucocorticoid* OR corticosteroid* OR methylprednisolone’ AND ‘COVID-19 OR coronavirus disease 2019 OR novel coronavirus OR SARS-CoV-2 OR severe acute respiratory syndrome coronavirus 2’. We also performed a manual search of the reference list of included studies to avoid the omission of any eligible study. Furthermore, we searched country-specific healthcare databases or public reports to identify original data that met the eligibility criteria.

Two authors (SSH, CSK) independently screened the PubMed and Google Scholar, two authors (SSH & HAM) screened the Dimensions database, and two authors (SSH and FM) screened the country-specific healthcare databases and public reports, to identify relevant articles. CSK assessed all the studies or reports published in the Chinese language (CSK’s native language). At the first stage, we screened the titles and abstracts to filter out the studies that were irrelevant to the aim of the review. In the next stage, potentially relevant articles and reports were accessed for full-text review. In case of any discrepancies and doubts about the relevance of the sources, a third author was involved to resolve by consensus.

2.2. Inclusion and exclusion criteria

Studies or reports eligible for our systematic review included peer-reviewed studies of any design (randomized controlled trial, prospective, retrospective, cohort, case-control, case series, narrative review, country-specific public reports) which reported or consisted of original data on (i) the mortality rate of COVID-19 patients who developed ARDS; or (ii) the mortality rate of COVID-19 patients (with or without ARDS) who reported to have received systemic corticosteroids treatment. We excluded preprints that were yet to complete peer-review process, editorials, correspondences, and commentaries, as well as any overlapping or duplicate studies. Studies involving only pediatric patients or patients with only certain comorbidities (eg, cancer, liver cirrhosis) which may not reflect the true mortality rates were also excluded. We excluded studies which reported inhaled corticosteroids use since they were most likely to be indicated for underlying chronic respiratory diseases instead of indicated for COVID-19 treatment, and the systemic effects of inhaled corticosteroids are limited.

2.3. Quality assessment

The quality assessment of individual studies was conducted using the Newcastle–Ottawa Scale (NOS) for cohort studies because of the unavailability of quality assessment tool for retrospective studies [27]. The NOS is easy to use with its star rating system and considered reliable to measure biases in cohort studies. Each of the selected retrospective cohort studies was evaluated for selection of study group (0–4 stars), comparability or quality of adjustment for confounding factors (0–2 stars), and ascertainment of the outcome of interest (0–3 stars), with a maximum of nine stars representing the highest methodological quality. Pairs of authors independently conducted the quality assessment for each included original study. Any disagreements were discussed between the two authors, and a third author was involved to reach a final judgment where required.
2.4. Data extraction and analysis

The relevant data from all the retrieved studies and reports were extracted, and systematically collected and tabulated using Microsoft Excel and are presented in Table 1. The extracted information included the name of the first author or institutes, country, and region, study type, study site, age, study period, the total number of patients, number of patients with ARDS, number of deaths in patients with ARDS, number of patients receiving corticosteroid therapy, and the number of deaths in patients receiving corticosteroid therapy.

The outcome measure was the pooled mortality estimate among individuals with COVID-19 who developed ARDS. Due to uncertainty and heterogeneity in terms of indications, dosing regimen, disease stage at which corticosteroid was administered, and the type of corticosteroid used, the mortality among individuals with COVID-19 who received corticosteroid therapy could not be pooled in a meta-analysis. Thus, mortality among individuals with COVID-19 who received corticosteroid therapy in each study was presented as descriptive statistics, with critical review and discussion on the role of corticosteroid therapy in COVID-19. All meta-analytical calculations were performed using Meta XL, version 5.3 (Epigear International, Queensland, Australia) [28]. The proportion of individuals with COVID-19 who developed ARDS and reported death in each country was first calculated, before combining country-specific proportions to give a pooled mortality estimate of ARDS across all countries. Subgroup analysis of mortality estimate of ARDS was performed by pooling studies from Asia and from Europe only. We employed a random-effects model to estimate the pooled mortality of COVID-19-associated ARDS and to generate a forest plot of the pooled mortality estimate with 95% confidence intervals (CIs) [29]. We examined the heterogeneity between studies using the I² statistics with 50% and the χ² test with p < 0.10, as the thresholds for statistically significant heterogeneity [30].

3. Results

3.1. Search results

Our search yielded 17,046 titles from the selected databases (Figure 1), of which 8,893 titles were duplicates. The remaining 8,153 records were screened as per PRISMA guidelines against the eligibility criteria described in the previous section. A total of 7,808 records were excluded after reading the title and abstract. The full texts of the remaining 345 articles were retrieved for a detailed evaluation. We finally identified 37 articles for the qualitative synthesis [31–67].

Amongst these 37 articles, 26 articles (25 original studies and 1 narrative review) reported mortality in COVID-19 patients with ARDS (with or without corticosteroid use) and were selected for further quantitative analysis [31–36,39–41,43–46,48–50,52–56,58–62]. In addition, we also retrieved two national reports, one each from France [68] and Spain [69] that were also included in the quantitative synthesis of mortality in COVID-19 associated ARDS.

Together, the included articles/reports evaluated 10,815 COVID-19 patients with ARDS for quantitative synthesis of mortality with ARDS and 2,489 COVID-19 patients (with or without ARDS) for qualitative synthesis of mortality from corticosteroid use.

3.2. Quality assessment

The Newcastle–Ottawa scale was applied for the quality assessment (supplementary data, Table S1) of studies included in the quantitative synthesis of mortality in COVID-19 patients with ARDS. Of the 25 original studies included in the meta-analysis, 16 studies were deemed ‘good’ studies with a score of seven points [31,33–35,40,41,44–46,49,50,52,53,56,58,60] (Table 1). Whereas the remaining 9 studies were regarded as ‘fair’ with a score of 6 points [32,36,39,43,48,54,59,61,62] (Table 1). There was no study categorized as ‘poor’ (i.e., scored less than five points). The quality issue identified in the ‘fair’ studies [32,36,39,43,48,54,59,61,62] was the inadequate follow-up as these studies did not follow all patients from enrollment to discharge (or death) (Table S1). In addition, the comparability item was not assessed due to the absence of control or comparator.

3.3. Characteristics of the included studies

The characteristics of the included studies are shown in Table 1. All of the included original studies were published in 2020 with a wide range of sample sizes from 15 to 1,859. The median/mean ages of subjects were above 40 years old in all original studies.

Among the 26 original articles which reported mortality in COVID-19 patients with ARDS, 25 were original studies [31–36,39–41,43–46,48–50,52–56,58–62], including 19 studies (76%) [31–36,39–41,43–46,48–50,52–54] from China, of which 16 studies (64%) [31–36,39–41,44–46,49,50,52,53] were conducted in the Wuhan city. The remaining 6 studies were from Italy (n = 3 [58–60]), Germany (n = 1) [61], Poland (n = 1) [62], and Iran (n = 1) [56]. In addition, only 10 out of the 25 original studies are multicenter [34,35,41,44–46,48,49,54,56], while the remaining 15 studies are single-center [31–33,36,39,40,43,50,52,53,58–62]. One of the datasets from Iran on mortality in COVID-19 patients with ARDS was retrieved from a narrative review article [55] which described the Iranian treatment protocol for COVID-19 induced ARDS. The French data on mortality in COVID-19 patients with ARDS (up to 31 May 2020) were retrieved from a weekly report published by the National Public Health Agency of France based on their sentinel surveillance of COVID-19 patients admitted for intensive care [68]. The Spanish data on mortality in COVID-19 patients with ARDS (up to 21 May 2020) were retrieved from a weekly report published by the National Center of Epidemiology of Spain based on their epidemiological survey on COVID-19 patients [69]. Except for two studies [59,60] which included exclusively COVID-19 patients with ARDS, the crude prevalence of ARDS in the remaining 26 articles/reports ranged from 2% to 79%, with a median prevalence of 35% (lower quartile: 18%; upper quartile: 44%).

On the other hand, there are 23 studies [31,33–35,37,38,40–42,44–47,49,51,52,54,57,63–67] included which reported mortality with corticosteroids use in COVID-19 patients (with or without ARDS), in which 17 out of 23 studies (74%) were originated from China [31,33–35,37,38,40–42,44–47,49,51,52,54], where all but
Table 1. Characteristics of included studies presenting proportion of COVID-19 patients with ARDS and COVID-19 patients receiving corticosteroids.

| Study       | Region, Country | Study Type                     | Study Site          | Age* | Study Period                     | No. of patients with ARDS | No. of deaths in patients with ARDS | Corticosteroids dosing regimen | Mortality in corticosteroids group N/N (%) | NOS Quality Score |
|-------------|-----------------|--------------------------------|---------------------|------|---------------------------------|---------------------------|-----------------------------------|-------------------------------|-------------------------------------------|------------------|
| Wu et. al [31] | Wuhan, China   | Retrospective cohort study    | Single center       | 51 (43–60) | 25 December 2019–13 February 2020 | 201                       | 84                                | 44                           | MTP, dose not mentioned                     | 23/50 (46.0)     | 7     |
| Chen N et. al [32] | Wuhan, China   | Retrospective cohort study    | Single center       | M(SD): 55.5 (13.1) | Jan 1–20 January 2020 | 99                        | 17                                | 11                           | -                                         | -                | 6     |
| Yang et. al [33] | Wuhan, China   | Retrospective cohort study    | Single center       | M(SD): 59.7 (13.3) | 24 December 2019, to 26 January 2020 | 52                        | 35                                | 26                           | No information                            | 16/30 (53.3)     | 7     |
| Zhou et. al [34] | Wuhan, China   | Retrospective cohort study    | Multicenter         | 56 (46–67) | 29 December 2019–31 January 2020 | 191                       | 59                                | 50                           | No information                            | 26/57 (45.6)     | 7     |
| Deng et. al [35] | Wuhan, China   | Retrospective cohort study    | Multicenter         | 54 (47–65) | 1 January 2020–21 February 2020 | 225                       | 108                               | 98                           | No information                            | 88/152 (57.9)    | 7     |
| Tang et al [36] | Wuhan, China   | Retrospective case-cocontrol study | Single center | 62 (47–69) | 24 December 2019–7 February 2020 | 179                       | 73                                | 21                           | -                                         | -                | 6     |
| Wang Yin et al [37] | Wuhan, China   | Retrospective cohort study    | Single center       | 54(48–64) | Jan 20 – Feb 25, 2020 | 46                        | -                                 | -                           | MTP 1–2 mg/kg/d for 5–7 d                | 2/26 (7.7)       | -     |
| Huang C et al [38] | Wuhan, China   | Prospective study             | Single center       | 49 (41–58) | 16 December 2019–2 January 2020 | 41                        | -                                 | -                           | MTP 40–120 mg/d                          | 4/9 (44.4)       | -     |
| Wang L et al [39] | Wuhan, China   | Prospective study             | Single center       | 69 (65–76) | Jan 1 – Mac 5, 2020          | 339                       | 71                                | 56                           | -                                         | -                | 6     |
| Cao et al [40] | Wuhan, China   | Cohort study                  | Single center       | 54(37–67) | Jan 3–1 February 2020        | 102                       | 20                                | 15                           | MTP, dose not mentioned                     | 11/51 (21.6)     | 7     |
| Wang D et al [41] | Wuhan, China   | Retrospective case series     | Multicenter         | 51(36–65) | Jan 1–10 February 2020       | 107                       | 28                                | 17                           | No information                            | 18/62 (29.0)     | 7     |
| Li et al [42] | Wuhan, China   | Retrospective cohort study    | Single center       | M(SD): 51.0 (17.5) | Jan 10–22 February 2020 | 93                        | -                                 | -                           | No information                            | 21/21 (100)      | -     |
| Wan et al [43] | Chongqing, China | Retrospective case series    | Single center       | 47(36–55) | Jan 23–8 February 2020       | 135                       | 21                                | 1                           | -                                         | -                | 6     |
| Xu et al [44] | Wuhan, China   | Retrospective cohort study    | Multicenter         | M(SD): 62.5 (13.3) | Jan 12–3 February 2020 | 239                       | 164                               | 118                          | MTP 60.9 ± 21.7 mg/d                     | 118/189 (62.4)   | 7     |
| Chen L et al [45] | Wuhan, China   | Retrospective cohort study    | Multicenter         | 59(45–68) | Jan 20–4 April 2020         | 1859                      | 227                               | 174                          | No information                            | 165/753 (21.9)   | 7     |
| Shi Q et al [46] | Wuhan, China   | Retrospective cohort study    | Multicenter         | Diabetes: 64(56–72), Non-diabetes: 65(56–72) | Jan 1 – Mac 8, 2020 | 306                       | 55                           | 47                          | No information                            | 30/107 (28.0)    | 7     |
| Chen F et al [47] | Wuhan, China   | Retrospective cohort study    | Single center       | 55(34–68) | Jan 1–15 February 2020       | 660                       | -                                 | -                           | No information                            | 30/184 (16.3)    | -     |
| Shi M et al [48] | Hubei, China   | Retrospective cohort study    | Multicenter         | M(SD): 59.4 (16.5) | Jan 1 – Mac 1, 2020 | 161                       | 69                                | 47                           | -                                         | -                | 6     |
| Ruan et al [49] | Wuhan, China   | Retrospective cohort study    | Multicenter         | Died: 67(15–81), Discharged: 30(44–81) | No information | 150                       | 62                                | 55                          | No information                            | 31/53 (58.5)     | 7     |
| Wang Yang et al [50] | Wuhan, China   | Retrospective cohort study    | Single center       | 60(48–69) | Jan 25–25 February 2020 | 344                       | 145                               | 128                          | -                                         | -                | 7     |
| Yan et al [51] | Wuhan, China   | Retrospective cohort study    | Single center       | 64(49–73) | Jan 10–24 February 2020 | 48                        | -                                 | -                           | No information                            | 35/39 (89.7)     | -     |
| Wang K et al [52] | Wuhan, China   | Ambispective cohort study     | Single center       | Died: 58(46–67), Survived: 67(62–78) | No information | 548                       | 207                               | 76                          | No information                            | 65/341 (19.1)    | 7     |
Table 1. (Continued).

| Study                  | Region, Country       | Study Type       | Study Site                              | Age | Study Period                  | No. of patients | No. of patients with ARDS | No. of deaths in patients with ARDS | Corticosteroids dosing regimen | Mortality in corticosteroids group n/N (%) | NOS Quality Score |
|------------------------|-----------------------|------------------|-----------------------------------------|-----|------------------------------|----------------|---------------------------|-----------------------------------|-------------------------------|------------------------------------------|-------------------|
| Pan et al [53]         | Wuhan, China          | Case-control     | Single center                           | 68 (61–75) | Jan 27 – Mac 19, 2020       | 124            | 91                        | 89                                | -                             | -                                         | 7                 |
| Huang M et al [54]     | Jiangsu, China        | Retrospective cohort study | Single center Multicenter | 57 (26–97) | Jan 24–20 April 2020 | 60             | 9                         | 0                                | No mention of agent used; 40 to 80 mg/d | 0/34 (0)                    | 6                       |
| Jamaati et al [55]     | Iran                  | Descriptive      | Single center                           | -   | Up to Mac 3, 2020            | 231            | 72                        | 18                                | -                             | -                                         | -                 |
| Javanian et al [56]    | Iran                  | Retrospective cohort study | Single center Multicenter | M(SD): 60.1 (13.9) | Feb 25 – Mac 17, 2020 | 100            | 4                         | 3                                | -                             | -                                         | 7                 |
| Yang et al [57]        | Montreal, Canada      | Retrospective case study | Single center                           | -   | NC                           | 15             | -                         | -                                | MTP, HYC, DEX, Dose: 40–160 mg/d | 3/15 (20.0)                | -                  |
| Inciardi et al [58]    | Lombardy, Italy       | Retrospective case study | Single center                           | -   | Mar 4 – Mac 25, 2020         | 99             | 19                        | 18                                | -                             | -                                         | 7                 |
| Zangrillo et al [59]   | Milan, Italy          | Retrospective case study | Single center                           | -   | Feb 20–2 April 2020          | 73             | 73                        | 17                                | -                             | -                                         | 6                 |
| Cavali et al [60]      | Milan, Italy          | Retrospective cohort study | Single center | Standard treatment: 70 (64–78) | Mar 2020 | 45 | 45 | 10 | - | - | 7 |
| Dreher et al [61]      | Aachen, Germany       | Retrospective cohort study | Single center                           | 65 (58–76) | Feb – Mar 2020               | 50             | 24                        | 3                                 | -                             | -                                         | 6                 |
| Nowak et al [62]       | Warsaw, Poland        | Retrospective cohort study | Single center                           | M(SD): 63.7 (19.6) | Mar 16–7 April 2020 | 169            | 41                        | 30                                | -                             | -                                         | 6                 |
| National Public Health Agency of France [68] | Nationwide | Sentinel surveillance of COVID-19 patients admitted to intensive care | Nationwide | - | Mar 16–31 May 2020 | 4,007 | 3,185 | 593 | - | - | |
| National Center of 2,335 | France               | Epidemiology survey | Spain | Epidemiological survey | Nationwide | - | Up to 12:00 21 May 2020 | 250,287 | 5,807 | |
| Cruz et al [63]        | Madrid, Spain         | Retrospective cohort study | Single center | Corticosteroids: M(SD): 65.4 (12.9) | Mar 4–7 April 2020 | 463 | - | - | | |
|                         |                       |                  |                                          | Non- | Corticosteroids: M(SD): 68.1 (15.7) |                 |               |                  |          |               |          |
|                         |                       |                  |                                          | -   | No mention of agents used; pulse therapy or 1 mg/kg/d | 55/396 (13.9) | - | - | | | |
| Rubi et al [64]        | Granada, Spain        | Retrospective cohort study | Single center | M(SD): 63.9 (12.9) | - | 92 | - | - | | 6/83 (7.2) | |
| Selvaraj et al [65]    | Rhode Island, USA     | Case series      | Single center                           | M(SD): 60.0 (15.8) | Apr 16–16 May 2020 | 21             | -                         | -                                | DEX 4 mg three times daily for two days, followed by 4 mg twice daily for two days and then 4 mg once daily for two days | 0/21 (0)                | - |

(Continued)
| Study       | Region, Country | Study Type         | Study Site         | Age\(^a\)       | Study Period | No. of patients | No. of patients with ARDS | No. of deaths in patients with ARDS | Corticosteroids dosing regimen                               | Mortality in corticosteroids group n/N (%) | NOS Quality Score\(^b\) |
|------------|-----------------|--------------------|--------------------|-----------------|--------------|-----------------|--------------------------|-----------------------------------|------------------------------------------|------------------------------------------|-----------------------------|
| So et al [66] | Tokyo, Japan    | Case series        | Single center      | 64(47–73)       | Mar 2020     | 7               | -                        | -                                 | Pulse therapy: MTP 1000 or 500 mg/d for three days, followed by 1 mg/kg/d, then tapered off | 0/7 (0)                                 | -                           |
| Lee et al [67] | Daegu/ Gyeongsangbuk-do, Korea | Retrospective cohort study | Multicenter       | 72              | (68–79)      |                |                          | 15/28 (53.6)                    | Feb 18–4 March 2020                      | 98                                 | -                           |

ARDS = acute respiratory distress syndrome; DEX = dexamethasone; HYC = hydrocortisone; M = mean; MTP = methylprednisolone; PRED = prednisolone; SD = standard deviation  
\(^a\)Age was reported as median (lower quartile-upper quartile) unless otherwise indicated.  
\(^b\)Only for original studies included in the meta-analysis to determine mortality estimates of ARDS in COVID-19 (7 = good studies; 5–6 = fair studies; 0–4 = poor studies)
one [54] were conducted in the Wuhan city of China. The remaining six studies were originated from Spain (n = 2) [63,64], Canada (n = 1) [57], United States (n = 1) [65], Japan (n = 1) [66], and Korea (n = 1) [67]. Furthermore, 10 out of 23 studies are multi-center [34,35,41,44–47,49,54,67], while the remaining 13 studies are single-center [31,33,37,38,40,42,51,52,57,63–66]. Except for three studies [57,65,66] which included exclusively COVID-19 patients who received corticosteroids, the crude prevalence of corticosteroid use in the remaining 20 studies ranged from 22% to 90%, with a median prevalence of 53% (lower quartile: 29%; upper quartile: 66%).

3.4. Mortality estimate of COVID-19 patients with ARDS

The mortality data in the original articles and national reports [31–36,39–41,43–46,48–50,52–56,58–62,68,69] among COVID-19 patients with ARDS are summarized in Table 1. The pooled mortality estimate among COVID-19 patients with ARDS across all countries was 39% (95% CI: 23–56%; Figure 2). China had the highest mortality estimate among COVID-19 patients with ARDS of 69% (95% CI: 67–72%; Figure 2). In Europe (Figure 2), the highest mortality estimate among COVID-19 patients with ARDS was reported in Poland (73%; 95% CI: 58–86%), followed
by Spain (40%; 95% CI: 39–41%), and France (19%; 95% CI: 17–20%). Germany was found to have the lowest mortality estimate among COVID-19 patients with ARDS (13%; 95% CI: 2–29%). Subgroup analysis which limited only to the studies from Asia (China and Iran) involving COVID-19 patients with ARDS [31–36,39–41,43–46,48–50,52–56] presented a mortality estimate of 65% (95% CI: 53–76%). Subgroup analysis which limited only to the studies/reports involving COVID-19 patients with ARDS from European countries [58–62] reported a mortality estimate of 34% (95% CI: 20–50%).

3.5. Mortality in COVID-19 patients (with or without ARDS) with reported corticosteroid use

The 23 studies [31,33–35,37,38,40–42,44–47,49,51,52,54,57,63–67] that reported on mortality among COVID-19 patients (with or without ARDS) with systemic corticosteroid use are summarized in Table 1. Most of the studies included no information on the dosing regimen of systemic corticosteroid therapy [33–35,41,42,45–47,49,51,52,67]. Studies that included this information [30,37,38,40,43,48,50] reported a range of corticosteroids (methylprednisolone [31,37,38,40,44,45,47,57,66], prednisolone [66], hydrocortisone [57], and dexamethasone [57,65]) with varying doses and durations of treatment. Four studies reported the use of pulse corticosteroid therapy [63–66]. Only six studies specified explicitly that corticosteroid therapy was intended for COVID-19 [37,51,63–66]. Except for one study [31] that reported mortality from corticosteroid use exclusively in COVID-19 patients with ARDS (46%), the remaining 22 studies reported the use of corticosteroids in COVID-19 patients with or without ARDS. The reported crude mortality rates of COVID-19 patients (with or without ARDS) with corticosteroid use from the included studies were very broad and ranged from as low as 0% to as high as 100%. The median crude mortality rate of COVID-19 patients with reported corticosteroid use was 28.0% (lower quartile: 13.9%; upper quartile: 53.6%).

4. Discussion

This systematic review and meta-analysis present the pooled mortality estimates among COVID-19 patients with ARDS. The overall pooled mortality estimate of COVID-19 associated ARDS (39%) was comparable to the in-hospital mortality rate of patients with all-cause ARDS (non-COVID-19) managed with currently optimal therapies which include intensive care admission and mechanical ventilation, as reported in a recent systematic review (45%) [70] and the 2016 LUNG SAFE study (40%) [71].

The highest country-specific mortality from COVID-19 associated ARDS was found in China, which may be due to a lack of understanding of the origin and pathophysiology of the infection by SARS-CoV-2, as well as its management during the early outbreak of COVID-19. Of the 19 original Chinese studies included, all but two are originated in Hubei province (Wuhan is the capital city of Hubei province) [31–36,39–41,44–46,48–50,52,53], the epicenter of the COVID-19 outbreak. In fact, the study of Chen N et al. [32] included a cluster of patients (49% of total patients included) who had a history of exposure to the Huanan seafood market, which is referred to as the ‘ground zero’ of the COVID-19. The pooled mortality estimate of ARDS in COVID-19 patients from Chinese studies (69%) was higher than the previously reported mortality rate of Chinese patients with non-COVID-19 related sepsis and ARDS (42%) from a recent single-center prospective study [72]. This coincides with the reason detailed above for high mortality of ARDS in COVID-19 in China where the understanding toward pathophysiology and management of sepsis (non-COVID-19 related) was far more established than COVID-19. In fact, the lower pooled mortality estimate of ARDS in European studies (34%) relative to Chinese studies may be due to a better understanding of the management of COVID-19 when the epicenter of COVID-19 shifted from China to Europe.

The mortality estimate of ARDS in COVID-19 in France (19%) was much lower than the previously reported mortality rate among patients with all-cause ARDS (non-COVID-19) admitted to intensive care units in a French multicenter, prospective cohort study [73] (34%). However, the prospective study [73] included data spanning from the year 1997 to 2014, in which the role of lung-protective mechanical ventilation had yet to be established for most of the study duration (before 2010s) and thus may account for the reported higher mortality rate. On the other hand, a German-wide multi-center prospective cohort study (DACAPO study [74]) which evaluated the influence of quality of intensive care on patients with

![Figure 2. Pooled mortality estimate (%) in COVID-19 patients with ARDS (Heterogeneity: $I^2 = 100%$; $p = 0.001$).](image-url)
all-cause ARDS (non-COVID-19) reported a mortality rate of 27% in this cohort of patients, which was higher than the observed mortality estimate of COVID-19 associated ARDS in Germany (13%). Nevertheless, the German mortality estimate of ARDS in COVID-19 was originated from only one study [61], which included only 24 COVID-19 patients with ARDS, and therefore may be subject to high risk of selection biases.

The mortality estimate of COVID-19 associated ARDS in Iran (28%) was comparable to the mortality rate of hospitalized patients with ARDS due to H1N1 influenza (34%) as reported in a single-center, cross-sectional study [75] in Iran.

The difference in mortality estimates of COVID-19 associated ARDS among countries may be explained by the setting where patients with ARDS were receiving care since the management of ARDS requires a well-organized and advanced level of care. The exceptionally high mortality estimate of COVID-19 associated ARDS (73%) in Poland may be due to the small study size, and the fact that not every patient who developed ARDS received intensive care (41 patients with ARDS but only 27 patients were admitted into intensive care units, and hence the remaining 14 patients may have received suboptimal care) [62]. Indeed, the French and German mortality data were derived exclusively from ARDS patients admitted to the intensive care units which may have contributed to the relatively lower mortality estimate of COVID-19 associated ARDS in France (19%) and Germany (13%). A previous study [76] has reported lower death rates from ARDS among patients admitted to high-volume intensive care units than low- and moderate-volume ICUs. Though the study compared among different intensive care units, it did suggest that settings with high case volume may affect the quality of care of patients with ARDS and medical wards typically have higher case volume than intensive care units.

The high mortality rate in COVID-19 associated ARDS necessitates a prompt and aggressive treatment strategy. It has long been our understanding that inflammation is the key factor that drives the pathophysiology of ARDS, irrespective of the etiology [77]. Further examination of the inflammatory cascade reveals that insufficient glucocorticoid receptor-mediated inhibition of proinflammatory NF-kB may be central to the pathogenesis of ARDS [78]. This necessitates consideration for the administration of corticosteroid therapy to prevent death. The current recommendation by WHO was against the routine use of corticosteroids in COVID-19 associated pneumonia outside of clinical trials [21]. However, such recommendation requires a review especially in a subpopulation of COVID-19 patients with ARDS which may benefit from corticosteroid therapy. A 2018 meta-analysis [79] which included nine randomized trials of corticosteroid therapy (low-dose methylprednisolone) in patients with all-cause ARDS (non-COVID-19) has not only shown a significant reduction in mortality (risk ratio = 0.68; 95% CI: 0.57–0.82) but also improved time to extubation and duration of hospitalization. Treatment was generally well-tolerated except transient hyperglycemia that was the most common adverse effect reported. Similarly, a recent meta-analysis [80] with seven randomized controlled trials in patients with all-cause ARDS (non-COVID-19) reported reduced all-cause mortality (risk ratio = 0.75; 95% CI: 0.59–0.95), duration of mechanical ventilation (mean difference: −4.93 days; 95% CI: −7.81 days to −2.06 days), and increased ventilator-free days (mean difference: 4.28 days; 95% CI: 2.67 days to 5.88 days), with any type of corticosteroid therapy compared to placebo. Nevertheless, it was also observed that corticosteroid therapy slightly increased the risk of hyperglycemia (risk ratio = 1.12%; 95% CI: 1.01 to 1.24). Since a preliminary comparison of plasma cytokine profile found no significant difference between patients with COVID-19 receiving intensive care (n = 9; 67% with ARDS) and patients with non-COVID-19 associated sepsis (n = 28; 43% with ARDS) [81], the benefits of corticosteroid therapy are likely to extend to patients with COVID-19 associated ARDS. Wu C et. al [31] found that methylprednisolone (dose and regimen were not reported) reduced the risk of death in patients with COVID-19-associated ARDS (hazard ratio [HR] = 0.38; 95% CI: 0.20–0.72). However, without adjustment of potential confounders, the findings of the study should be treated with caution.

The recommendation by WHO to avoid the routine use of corticosteroid therapy in COVID-19 was due to a lack of evidence of effectiveness and possible harm [21]. Nevertheless, the systematic review of corticosteroid therapy among SARS patients which formed the basis for the WHO’s recommendation included many studies where the findings were inconclusive [20]. In fact, many have ignored the positive findings of a large-scale database study reported by Long et al. [82] in 2016 that evaluated the efficacy of corticosteroid therapy among 5,327 patients with SARS. This study was not included in the 2006 aforementioned systematic review. After adjustment for possible confounders in this study, it was reported that corticosteroid therapy significantly reduced the risk of mortality by 47% (HR = 0.53, 95% CI: 0.35–0.82) in severe cases of SARS, albeit no difference was noted in the risk of mortality in non-severe cases.

Whilst we found a wide range of crude mortality rates in COVID-19 patients receiving corticosteroids (with or without ARDS) in our systematic review, the largest studies from China included in our systematic review reported crude mortality rates of 21.9% [45]. An indirect comparison with the case fatality rate in COVID-19 patients who developed severe illness in China (49.0%) [83] hinted toward possible benefits of corticosteroid therapy since the recommendation by the National Health Commission of China [84] was to consider administration of corticosteroids in COVID-19 patients with rapid deterioration. In fact, Cruz et al. [63] in their retrospective cohort study of 463 COVID-19 patients in Spain reported significantly reduced odds of in-hospital mortality in COVID-19 patients receiving corticosteroid therapy upon adjustment of potential confounders (odds ratio = 0.19; 95% CI: 0.05–0.74), with no difference in mortality between pulse and non-pulse corticosteroid therapy. To the best of our knowledge, this was the only study thus far at the time of writing this article that provided adjusted mortality estimate among COVID-19 patients receiving corticosteroids.

It is likely that corticosteroid therapy was only administered during the very late stages of COVID-19 when other recommended interventions lead to little or no improvement, where
the full potential benefits of corticosteroid therapy may not be demonstrable. This may be due to WHO’s recommendations against using corticosteroids in COVID-19 patients. In fact, Zhang et al. [85] in their single-center, retrospective case series study reported that severely ill COVID-19 patients with multi-organ failure who died in intensive care unit had a mean delay of 1.5 days in the initiation of corticosteroid therapy compared to patients who had improved in the intensive care unit and transferred to the general wards. Though the findings from the study should not be treated as conclusive, it did suggest that future studies should compare the clinical outcomes between early and late administration to inform the appropriate timing for administration of corticosteroids in severely ill COVID-19 patients since corticosteroid therapy may not be very effective in the late stages of COVID-19 to contain the overwhelming production of cytokine.

Corticosteroid therapy was also associated with improvement in clinical outcomes other than mortality among severely ill COVID-19 patients with or without ARDS. Zhou et al. [86] reported an improvement in oxygen saturation (SaO₂) and arterial oxygen tension (PaO₂) inspiratory oxygen fraction (FiO₂) with corticosteroid therapy in 15 patients with COVID-19 complicated by ARDS. So et al. [66] in their case series of 7 mechanically ventilated COVID-19 patients with ARDS reported complete withdrawal of ventilator support in all cases within seven days of treatment with intravenous pulse therapy of methylprednisolone (1000 or 500 mg/day of methylprednisolone for three days intravenously, followed by 1 mg/kg once daily, then tapered by 10 or 20 or 30 mg/day of prednisolone orally, finishing at 10 mg of prednisolone), along with a reduction in median C-reactive protein levels. A retrospective, observational, single-center study by Wang Yin et al. [37] also reported a significantly faster resolution of symptoms (shorter time to normalize body temperature), faster improvement of SaO₂ and better improvement in the absorption degree of the focus in chest computed tomography among 46 severely ill COVID-19 patients receiving methylprednisolone (1–2 mg/kg/day for 5–7 days) compared to the control. Yang et al. [57] in their case series of 15 critically ill patients with COVID-19 noted an improvement in C-reactive protein level and PaO₂/FiO₂ upon administration of corticosteroid therapy. Selvaraj et al. [65] described a case series of 21 COVID-19 patients with hypoxic respiratory failure and reported a significant reduction in mean C-reactive protein levels compared to baseline with none of the patients required mechanical ventilation upon administration of dexamethasone (4 mg three times daily for two days, followed by 4 mg twice daily for two days and then 4 mg once daily for two days). Nevertheless, these studies [37,57,65,66,86] may be too small and may have potential selection biases therefore the findings cannot be treated as conclusive.

Despite the possible improvement in clinical outcomes, the best dosing regimen of corticosteroid therapy in patients with COVID-19 with severe manifestations of the disease is still not known. Lu et al. [87] in their case-control study which included 62 critically-ill COVID-19 patients (31 pairs with and without corticosteroid therapy matched by propensity score methods) noticed significantly elevated mortality risk (p = 0.003) with an increased dose of corticosteroids after adjustment for administration duration, with every 10 mg increment in equivalent hydrocortisone dose was associated with an additional 4% mortality risk (adjusted hazard ratio: 1.04, 95% confidence interval: 1.01–1.07). However, a case-control study with propensity score matching suffers inherently from the limitation that the analysis does not adjust other potential confounders that may exist, and therefore the findings from Lu et al. may not be conclusive. An ambispective cohort study [88] reported significantly higher risk of mortality in COVID-19 patients receiving high-dose corticosteroid therapy (the maximum dose was equivalent to or more than 1 mg/kg/day of prednisone) compared to no corticosteroid use (adjusted HR = 3.50; 95% CI: 1.79–6.86) in adjusted Cox proportional hazards regression analysis, while no difference in mortality was reported between low-dose corticosteroid therapy (the maximum dose was <1 mg/kg/day of prednisone) relative to no corticosteroid use (HR = 1.26, 95% CI: 0.61–2.58). Cruz et al. [63] who demonstrated a significant reduction in the mortality of COVID-19 patients receiving corticosteroid therapy employed either a regimen of 1 mg/kg/day of methylprednisolone or pulse corticosteroid therapy (unclear regimen). In the aforementioned study by Long et al. [82] on SARS patients, there was a significant reduction in the risk of mortality for both cohorts of SARS patients with severe disease receiving either average daily corticosteroid doses (equivalent methylprednisolone dose) of 80 mg/day or 160 mg/day, compared to no corticosteroid use, respectively, though no difference in the risk of mortality compared to no corticosteroid use beyond average daily corticosteroid doses of 160 mg/day.

Whether corticosteroid therapy is of benefit in COVID-19 patients with only mild-to-moderate manifestations of the disease is uncertain. Zha et. al [89] included 31 patients with mild COVID-19 disease (none reported ARDS) in their observational study, 11 of whom received corticosteroid therapy (methylprednisolone 40 mg once or twice daily) within 24 hours of admission for a median 5 days. There was no statistical difference in terms of viral clearance time, duration of symptoms, and length of hospital stay between corticosteroid arm and non-corticosteroid arm. Yuan et al. [90] included 35 pairs of propensity score-matched mild-to-moderate COVID-19 patients with and without corticosteroid treatment and reported no significant difference between the two groups with regards to progression to severe disease, length of hospital stay, duration of viral shedding, and duration of fever. However, both studies may be too small to conclude the efficacy of corticosteroid in COVID-19 patients with the mild-to-moderate illness. Nevertheless, extrapolation from SARS patients [69] suggested that corticosteroids do not reduce the risk of death in non-severe cases but any improvement in other clinical outcomes is unknown.

One of the concerns by WHO in corticosteroid therapy for COVID-19 patients was a possible delay in viral clearance, extrapolated from a multicenter, retrospective cohort study [91] of patients with the Middle East respiratory syndrome, though a closer examination of this study revealed no delay in viral clearance with corticosteroid therapy of more than 7 days. Nevertheless, mixed findings on viral clearance in
COVID-19 patients receiving corticosteroids had been reported. Ling et al. [92] observed that the duration of viral RNA detection for oropharyngeal swabs and feces in COVID-19 patients treated with a corticosteroid was longer than those without corticosteroid treatment (15 days vs. 8 days, \( p = 0.013 \) and 20 days vs. 11 days, \( p < 0.001 \) for oropharyngeal swabs and feces, respectively). However, the regimen of corticosteroid therapy was not mentioned by the authors in this study. Gong et al. [93] reported a significant delay in the negative conversion of viral nucleic acid testing among COVID-19 patients receiving methylprednisolone (1–2 mg/kg/day) than their counterparts without receiving methylprednisolone (29.11 ± 6.61 days versus 24.44 ± 5.21 days; \( p < 0.05 \)). Likewise, Chen X et al. [94] reported that corticosteroid treatment was associated with a significant delay (40%) in the negative conversion of viral nucleic acid testing among COVID-19 patients upon adjustment of co-variables (adjusted \( HR = 0.60; \) 95% CI: 0.39–0.94) though the regimen of corticosteroid therapy was not described. In contrast, both Shi et al. [95] and Xu et al. [96] reported no association between corticosteroid treatment (no mention of regimen) and duration of viral nucleic acid detection in their multivariable analysis (adjusted \( HR = 1.00; \) 95% CI: 0.53–1.89 and adjusted odds ratio = 1.38; 95% CI: 0.52–3.65, respectively). It is possible that the duration of viral shedding may be influenced by the dose of corticosteroid administered since Li et al. [97] reported that high-dose (80 mg/day, adjusted \( HR = 0.67; \) 95% CI: 0.46–0.96) but not low-dose corticosteroids (40 mg/day, adjusted \( HR = 0.72; \) 95% CI: 0.48–1.08) delayed viral shedding in patients with COVID-19, which may explain the increased risk of mortality with high-dose corticosteroid therapy as detailed beforehand. Fang et al. [98] compared the viral clearance time of COVID-19 corticosteroid users and non-corticosteroid users and reported no significant difference in both groups, stratified according to non-severe cases (17.6 ± 4.9 days vs. 18.7 ± 7.7 days) and severe cases (18.8 ± 5.3 days vs. 18.3 ± 4.2 days). Notably, non-severe COVID-19 corticosteroid users in the study received a median hydrocortisone-equivalent dose of 237.5 mg/day (interquartile range: 206.3–300.0 mg/day) for a median duration of 7 days (interquartile range: 5.5–8.0 days), while severe COVID-19 corticosteroid users received a median hydrocortisone-equivalent dose of 250.0 mg/day (interquartile range: 250.0–250.0 mg/day) for a median duration of 4.5 days (interquartile range: 3.5–5.8 days).

There are some limitations to this review that should be considered when interpreting the findings of this study. The majority of the original studies \( (17/23) \) reporting on mortality in COVID-19 patients with corticosteroid use originated from China \( [31,33–35,37,38,40–42,44–47,49,51,52,54] \) and therefore the results related to the use of corticosteroids may need a careful extrapolation to the global population. Nevertheless, we did include a relatively large study from Spain \( (n = 396) \) [63] which reported significantly reduced risk of mortality in COVID-19 patients upon adjustment of confounders. The results of original studies should be interpreted with caution as the details of corticosteroid therapy were not mentioned in many studies \( [33–35,41,42,45–47,49,51,52,67] \) making it difficult to determine the most appropriate treatment protocol for the corticosteroid therapy. Moreover, the use of the therapeutic intervention in the sickest patient and the small sample size may have also masked the beneficial effect of corticosteroid in some studies. Despite limited data was available, we managed to retrieve mortality data in COVID-19 patients with ARDS from six countries in addition to China and improved the reliability of the analysis presented in this article. Nevertheless, original studies that reported mortality in COVID-19 patients with ARDS with inadequate duration of follow-up \( [32,36,39,43,48,54,59,61,62] \) may have underestimated the mortality rate than if followed up until definite outcome (death/discharged).

## 5. Conclusion

The mortality estimate of COVID-19 patients with ARDS was similar to the present mortality rate of patients with all-cause, non-COVID-19 ARDS. It was still largely unknown whether the corticosteroid therapy could reduce the mortality risk of COVID-19 associated ARDS, albeit one study hinted on such a possibility. Improvement in other clinical outcomes (e.g. oxygenation indices, markers of inflammation, and resolution of signs and symptoms) in COVID-19 patients was also noted though without certainty due to methodological flaws. There is a need for a rigorously designed observational study, accounting for a range of co-variables and confounders, which details the dosing regimen and duration of corticosteroid therapy as well as the stage at which corticosteroid therapy is initiated, to reach firm conclusions. This is also the take-home message from this article.

## 6. Expert Opinion

The current COVID-19 pandemic adversely impacted upon economy and costed many lives across the world particularly in developed countries. One of the main causes of deaths in severely ill COVID-19 patients was ARDS, a result of uncontrolled inflammatory processes originating from the airways and the SARS-CoV-2 mediated cytokine storm. The mortality rate augmented due to the lack of an effective treatment led researchers to investigate the potential role of systemic corticosteroids to mitigate the cytokine storms in severely ill COVID-19 patients to prevent death. Indeed, this was initially received criticism and became controversial due to the obvious effects on corticosteroids on immunity and the potential for delayed viral clearance. The studies from previous viral outbreaks supported the notion that corticosteroid should not be used in COVID-19 patients due to the risks of delayed viral clearance. However, there was a dearth of high-quality data to evidence that the delayed viral clearance represents a significant prognostic factor of the disease, while patients deteriorated rapidly once cytokine storms developed, leading to ARDS mediated death. Therefore, the benefits of administration of systemic corticosteroids in severely ill COVID-19 patients outweighs the potential risk of delayed viral clearance.

Importantly, the role of systemic corticosteroids has been previously established before COVID-19 for the treatment of all-cause ARDS. Besides, extrapolation of data from patients...
with SARS observed the effectiveness of systemic corticosteroids among patients with severe illness. This systematic review provided further evidence of the effectiveness of low-dose corticosteroid therapy in reducing the risk of mortality in COVID-19 patients with severe course of illness including those who develop ARDS. Recently, the release of the results from a randomized controlled trial (RECOVERY [99]) on the use of dexamethasone demonstrated mortality benefits in a subset of COVID-19 patients receiving respiratory support, which supports the findings of this systematic review and meta-analysis, though the data from RECOVERY trial has yet to complete the peer-review process at the time of writing this article. Nevertheless, the current evidence supports the recommendations by the Society of Critical Care Medicine [100] in permitting the use of systemic glucocorticoids in patients with COVID-19 who have moderate-to-severe ARDS (patients with a partial arterial pressure of oxygen/fraction of inspired oxygen [PaO2: FiO2]<100 mmHg).

The worsening glycaemic control is anticipated with the systemic corticosteroids use in both diabetic and non-diabetic COVID-19 patients. Although, it is not in the scope of this systematic review to discuss the management of acute hyperglycaemia induced by systemic corticosteroids, we still foresee that the mortality benefits of corticosteroid therapy outweigh the risks of altered glycaemic control. Nevertheless, hyperglycaemia during hospitalization has been linked to a worse prognosis in COVID-19 patients, therefore, it is imperative that clinicians should be prepared to initiate or adjust insulin therapy based on the type of corticosteroid administered (i.e. either long- or short-acting), in order to maintain optimal glycaemic control during the course of treatment.

Funding
This paper was not funded.

Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions
SSH and CSK conceived the content, retrieved the data, wrote the manuscript, and approved the final version. HAM, RA, FM, and STRZ reviewed the data, revised the manuscript, and approved the final version.

ORCID
Syed Shahzad Hasan http://orcid.org/0000-0002-4058-2215
Syed Tabish Razi Zaidi http://orcid.org/0000-0002-2031-1055

References
Papers of special note have been highlighted as either of interest (-) or of considerable interest (••) to readers.

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30.; Lancet. 2020;395(10223):497-506.]
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020;323(11):1061–1069.
3. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore [published online ahead of print, 2020 Mar 3] [published correction appears in doi: 10.1001/jama.2020.4372]. JAMA. 2020;323(15):1488–1494.
4. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025–1031.
5. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar 31;368:m1295]. BMJ. 2020;368:m1091.
6. Mahase E. COVID-19: most patients require mechanical ventilation in first 24 hours of critical care. BMJ. 2020;368:m1201.
7. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a Report of 72 314 cases from the Chinese centre for disease control and prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020. DOI:10.1001/jama.2020.2648
8. Arentz M, Yim E, Klafl F, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State [published online ahead of print, 2020 Mar 19]. JAMA. 2020;323(16):1612–1614.
9. Bhatraju PK, Ghassemi B, Nichols M, et al. Covid-19 in critically ill patients in the Seattle Region - Case Series. N Engl J Med. 2020;382(21):2012–2022.
10. Grasselli G, Zangrillo a, Zanella a, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy [published online ahead of print, 2020 Apr 6]. JAMA. 2020;323(16):1574–1581.
11. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area [published correction appears in JAMA. 2003 Jul 16;290(3):334]. JAMA. 2003;289(21):2801–2809.
12. Chen CY, Lee CH, Liu CY, et al. Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome. J Chin Med Assoc. 2005;68(1):4–10.
13. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767–1772.
14. Sung JJ, Wu a, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004;59(5):414–420.
15. World Health Organization. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). Document WHO/CDS/CSR/GAR/2003.11 15 August 2003. [cited May 01 2020]. http://www.who.int/csr/sars/en/WHOconsensus.pdf
16. Centre for Evidence-Based Medicine. Global Covid-19 Case Fatality Rates. [cited May 25, 2020]. https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/
17. Yu WC, Hui DS, Chan-Yeung M. Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS). Thorax. 2004;59(8):643–645.
18. Van Reeth K, Van Gucht S, Penseaet M. Correlations between lung proinflammatory cytokine levels, virus replication, and disease after swine influenza virus challenge of vaccination-immune pigs. Viral Immunol. 2002;15(4):583–594.

19. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 2002;360(9348):1831–1837.

20. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.

21. World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Geneva: World Health Organization; 2020 [cited March 30, 2020]. https://www.who.int/publications-detail clinical-management-of-severe-acute-respiratory-infection-when Novel-Coronavirus (ncov)-infection-is-suspected

22. Jose RJ, Manuel a. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–e47.

23. Umberto Meduri G, Bell W, Sinclair S, et al. Pathophysiology of acute respiratory distress syndrome. Glucocorticoid receptor-mediated regulation of inflammation and response to prolonged glucocorticoid treatment. Presse Med. 2011;40(12 Pt 2): e543–e560.

24. Schwingenschlack a, Meduri GU. Rationale for Prolonged Glucocorticoid Use in Pediatric ARDS: what the Adults Can Teach Us. Front Pediatr. 2016;4:58.

25. Moher D, Liberati a, Tetzlaff J, et al., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;151(4):264-269.

26. Mouratidis RW. Dimensions. J Med Libr Assoc. 2019;107(3):459–461.

27. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. [cited April 1, 2020]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

28. MetaXL Version 5.3; 2019. [cited April 12, 2020]. https://www.epigear.com/index_files/metalx.html

29. DerSimonian R, Racker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28 (2):105–114.

30. Higgins JPT, Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011 Mar. [cited April 1, 2020]. http://www.cochrane-handbook.org

31. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [published online ahead of print, 2020 Mar 13]. JAMA Intern Med. 2020;180(7):1–11.

• The only study thus far at the time of writing which reported mortality outcomes of corticosteroid use in ARDS patients with COVID-19.

32. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395 (10223):507–513.

33. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med. 2020 Apr;8(4):e262]. Lancet Respir Med. 2020;8(5):475–481.

• This study included a cluster of patients who had a history of exposure to the Huanan seafood market, which is referred to as “ground zero” of the COVID-19.

34. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054–1062.

35. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J. 2020;133(11):1261–1267.

36. Tang X, Du R, Wang R, et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020;158(1):195–205.

37. Wang Y, Jiang W, He Q, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020;5(1):57.

38. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395 (10223):497–506.

39. Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639–645.

40. Cao J, Tu WJ, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(5):748–755.

41. Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 2020;24 (1):188.

42. Li L, Yang L, Gu S, et al. Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China. Theranostics. 2020;10(14):6113–6121.

43. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92 (7):797–806.

44. Xu J, Yang X, Yang L, et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care. 2020;24(1):394.

45. Chen L, Yu J, He W, et al. Risk factors for death in 1859 subjects with COVID-19. Leukemia. 2020;34(8):2173–2183.

46. Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a Two-Center, Retrospective Study. Diabetes Care. 2020;43 (7):1382–1391.

47. Chen F, Sun W, Sun S, et al. Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China [published online ahead of print, 2020 Jun 4]. Clin Transl Med. 2020. DOI:10.1002/ctm2.40

48. Shi M, Chen L, Yang Y, et al. Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: a multicenter descriptive study [published online ahead of print, 2020 Jun 21]. J Clin Lab Anal. 2020;32(4):458–464.

49. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published correction appears in Intensive Care Med. 2020 Apr 6]. Intensive Care Med. 2020;46(5):846–848.

50. Wang Y, Lu X, Li Y, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430–1434.

51. Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001343.

52. Wang K, Zhang Z, Yu M, et al. 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispeckle observational cohort study. Intensive Care Med. 2020;46(7):1472–1474.

53. Pan F, Yang L, Li Y, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. 2020;17(9):1281–1292.

54. Huang M, Yang Y, Shang F, et al. Clinical characteristics and predictors of disease progression in severe patients with COVID-19 infection in Jiangsu Province, China: a descriptive study. Am J Med Sci. 2020;369(2):120–128.

55. Jamaati H, Dastan F, Tabarsi P, et al. A fourteen-day experience with coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS): an Iranian treatment protocol. Iran J Pharm. 2020;19(1):31–36.

56. Javanian M, Bayani M, Shokri M, et al. Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study [published online ahead of
print, 2020 May 11]. Rom J Intern Med. 2020. //rjim-ahead-of-print /rjim-2020-0013/rjim-2020-0013.xml.
57. Yang SS, Lipes J. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series [published online ahead of print, 2020 May 11]. Can J Anesth. 2020;7:3.
58. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41(19):1821-1829.
59. Zangrillo a, Beretta L, Scandroglio AM, et al. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy [published online ahead of print, 2020 Apr 23]. Crit Care Resusc. 2020.
60. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19 acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331.
61. Dreher M, Kersten a, Bickenbach J, et al. The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS. Dtsch Arztebl Int. 2020;117(16):271–278.
62. Nowak B, Szymanski P, Parkowski I, et al. Clinical characteristics and short-term outcomes of coronavirus disease 2019: retrospective, single-center experience of designated hospital in Poland. Pol Arch Intern Med. 2020;130(5):407–411.
63. Cruz AF, Ruiz-Antorán B, Muñoz Gómez a, et al. Impact of glucocorticoid treatment in sars-cov-2 infection mortality: a retrospective controlled cohort study [published online ahead of print, 2020 Jun 22]. Antimicrob Agents Chemother. 2020;AAC.01168–20.
**The only study thus far at the time of writing which provided adjusted mortality estimate among COVID-19 patients who received corticosteroid therapy.**
64. Callejas Rubio JL, Luna Del Castillo JD, de la Hera Fernández J, et al. Effectiveness of corticosteroid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection [published online ahead of print, 2020 May 27]; Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2 [published online ahead of print, 2020 May 27]. Med Clin (Barc). 2020;S0025-7753(20)30283-9.
65. Selvaraj V, Dapaah-Afriyie K, Finn a, et al. Short-term dexametha- sone in Sars-CoV-2 Patients. R I M Med J. 2020;103(6):39–43.
66. So C, Ro S, Murakami M, et al. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respilior Case Rep. 2020;8(6):e00596.
67. Lee JY, Kim HA, Huh K, et al. Risk factors for mortality and respira- tory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci. 2020;35(23):e223.
68. National Public Health Agency of France. [COVID-19: epidemiological update as of May 21, 2020]; [cited July 9, 2020]. https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national-covid-19-point-epidemiologique-du-4-juin-2020
69. National Centre of Epidemiology. [Report on the situation of COVID-19 in Spain-COVID-19 Report No. 32 as of May 21, 2020]; [cited May 23, 2020]. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/InformeSARS-CoV-2/Informe%20SARS-CoV-2%2020200522.pdf.
70. Wu Z, Wu S, Li Q, et al. Prophylaxis with corticosteroids for COVID-19. J Antimicrob Chemother. 2020;75(4):757–767.
71. Li S, Zhao D, Cui J, et al. Prevalence, potential risk factors and mortality rates of acute respiratory distress syndrome in Chinese patients with sepsis. J Int Med Res. 2020;48(2):30006519895659.
72. Azoulay E, Lemiale V, Mourvillier B, et al. Management and outcomes of acute respiratory distress syndrome patients with and without comorbid conditions. Intensive Care Med. 2018;44(7):1050–1060.
73. Blecha S, Brandl M, Zeman F, et al. Tracheostomy in patients with acute respiratory distress syndrome is not related to quality of life, symptoms of psychiatric disorders or return-to-work: the prospective DACPO cohort study. Ann Intensive Care. 2020;10(1):52.
74. Nejad MA, Hashemian M, Ganjalikhanie H, et al. Evaluation of prevalence and severity of acute respiratory distress syndrome in hospitalized patients due to H1N1 outbreak in Kerman, Iran. Med Sci. 2020;24(101):135–142.
75. Dres M, Pham T, Aegerter P, et al. Effect of high-volume ICUls on mortality in ARDS over 15 years. Presented at: 2017 American Thoracic Society (ATS) International Conference, Washington, DC, May 19–24. Abstract 6524.
76. Suter PM. Lung inflammation in ARDS—friend or foe? N Engl J Med. 2006;354(16):1739-1742.
77. Leaver SK, Evans TW. Acute respiratory distress syndrome. BMJ. 2007;335(7616):389-394.
78. Meduri GU, Sieniutczuk RAC, Ness RA, et al. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018;6:53.
79. Mammen MJ, Aryal K, Alhazzani W, et al. Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. Pol Arch Int Med. 2020;130(4):276-286.
80. Wilson JG, Simpson LJ, Ferreira a, et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. medRxiv. 2020;0515.20103549.
81. Long Y, Xu Y, Wang B, et al. Clinical recommendations from an observational study on MERS: glucocorticoids was benefit in treating SARS patients. Int J Clin Exp Med. 2016;9(5):8865–8873.
**a large observational study which demonstrated mortality benefits with corticosteroid use in severe SARS patients.**
82. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — china, 2020 [J]. China CDC Weekly. 2020;2(8):113–122.
83. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7); [cited May 20, 2020]. https://www.chinadaily.com.cn/pdf/2020/1.ClinicalProtocols_for_the.Diagnosis_and.Treatment_of_COVID-19.pdf
84. Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364.
85. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticoste- roids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18.
86. Lu X, Chen T, Wang Y, et al. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit Care. 2020;24(1):241.
87. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118.
88. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–420.
89. Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis [published online ahead of print, 2020 Jun 2]. Shock. 2020. DOI:10.1097/SHK.0000000000001574.
90. Arabi YM, Mandoouh Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.
91. Ying Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J. 2020;133(9):1039–1043.
93. Gong Y, Guan L, Jin Z, et al. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old [published online ahead of print, 2020 May 22]. J Med Virol. 2020. DOI:10.1002/jmv.26052
94. Chen X, Zhu B, Hong W, et al. Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19 [published online ahead of print, 2020 Jun 30]. Int J Infect Dis. 2020;98:252–260.
95. Shi D, Wu W, Wang Q, et al. Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study [published online ahead of print, 2020 Jul 2]. J Infect Dis. 2020; jiaa388.
96. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020;71(15):799–806.
97. Li S, Hu Z, Song X. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19 [published online ahead of print, 2020 Jun 26]. Clin Infect Dis. 2020; ciaa829.
98. Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020;81(1):147–178.
99. Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. 2020;06:22.20137273.
100. Society of Critical Care Medicine (SCCM). Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). [cited April 30, 2020]. https://www.sccm.org/getattachment/Disaster/SSC-CoVID19-Critical-Care-Guidelines.pdf?lang=en-US